CompletedNCT03315897
Erythropoietin or Saline and Cognition in Bipolarity or Recurrent Depression
About this title
Read the official source — NCT03315897Medication studyAges 18–65Denmark
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- CopenhagenSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 5, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 103
- Sponsor
- Lars Vedel Kessing
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Denmark
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03315897
- Official title
Show the full official title
Effects of Erythropoietin on Cognitive Functions and Neural Activity in Cognitively Impaired Remitted Patients With Bipolar Disorder or Recurrent Depressive Disorder and Healthy People: Study Protocol for a Randomized, Controlled Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Copenhagen
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Lars Vedel Kessing.
Did this study involve medication?
Yes. The study involved medication, including Erythropoietin and Saline.
Who was this study for?
Listed age limits: 18 years to 65 years.
